Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair dose-ranging study in chronic idiopathic urticaria despite H1 antihistamines
2010-022782-99Phase 3
- Sponsor
- Genentech
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Genentech. Primary endpoint: Change in weekly itch score from baseline to Week 12.
02
Drugs
omalizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2010-022782-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022782-99.